Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Quinacrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.96 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.96 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.96 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.96 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.96 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.96 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.96 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.96 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.96 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.96 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.96 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.96 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.96 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.96 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.96 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.96 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.96 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.96 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.96 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinacrine SCHEMBL25334547 | 1.00 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL450737 | 1.00 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL7147117 | 1.00 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL7147115 | 1.00 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL30416460 | 1.00 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL28651594 | 0.99 | USP2 (0.98) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL30153780 | 0.99 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL162379 | 0.99 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL15061349 | 0.99 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL33693 | 0.99 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2191 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583875-A1 | CHEMICAL DISBUDDING METHOD | Welfare Concepts Limited (NZ) | 2025-07-16 | — | — | EP | claimed |
| WO-2025129271-A1 | LIPID DELIVERY VEHICLE | THE UNIVERSITY OF QUEENSLAND (AU) | 2025-06-26 | — | — | WO | claimed |
| CN-119924377-A | Preservative for picked bananas and application thereof | 广西壮族自治区农业科学院 | 2025-05-06 | — | — | CN | claimed |
| EP-4536236-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | University of Utah Research Foundation (US) | 2025-04-16 | — | — | EP | claimed |
| US-20240398801-A1 | TREATMENT OF LEUKEMIA BASED ON LEUKEMIA HIERARCHY IN A PATIENT | UNIVERSITY HEALTH NETWORK (CA) | 2024-12-05 | — | — | US | claimed |
| WO-2024102612-A1 | COMPOUNDS AND METHODS FOR IDENTIFYING COMPOUNDS FOR MODULATING GLUCOSE TRANSPORT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-16 | — | — | WO | claimed |
| CN-117731665-A | Application of quinacrine or pharmaceutically acceptable salt thereof in preparation of medicines for treating non-alcoholic fatty liver disease | 兰州大学 | 2024-03-22 | — | — | CN | claimed |
| CN-117717549-A | Application of quinacrine or pharmaceutically acceptable salt thereof in preparation of medicines for treating hyperlipidemia | 兰州大学 | 2024-03-19 | — | — | CN | claimed |
| WO-2024052765-A1 | CHEMICAL DISBUDDING METHOD | Welfare Concepts Limited (NZ) | 2024-03-14 | — | — | WO | claimed |
| CN-115590851-B | Application of 4- (4-diethylamino-1-methylbutylamino) -7-chloroquinoline derivative in preparation of medicines for treating obesity | 兰州大学 | 2023-12-29 | — | — | CN | claimed |
| JP-4217772-B2 | — | — | 2009-02-04 | — | — | JP | claimed |
| WO-2008127549-A1 | NEGATIVE-WORKING IMAGEABLE ELEMENTS AND METHODS OF USE | EASTMAN KODAK COMPANY (US) | 2008-10-23 | — | — | WO | claimed |
| US-20080038770-A1 | Cancer Stem Cells And Uses Thereof | HOSPITAL FOR SICK CHILDREN (CA) | 2008-02-14 | — | — | US | claimed |
| WO-2007079293-A2 | CANCER STEM CELLS AND USES THEREOF | HOSPITAL FOR SICK CHILDREN (CA) | 2007-07-12 | — | — | WO | claimed |
| US-20070123448-A1 | Novel chemical entities affecting neuroblastoma tumor-initiating cells | THE HOSPITAL FOR SICK CHILDREN (CA) | 2007-05-31 | — | — | US | claimed |
| US-20060034731-A1 | Sensor arrays for detecting analytes in fluids | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-02-16 | — | — | US | claimed |
| JP-2000516279-A | — | — | 2000-12-05 | — | — | JP | claimed |
| EP-0917549-A1 | AQUEOUS BONDING COMPOSITION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-05-26 | — | — | EP | claimed |
| WO-1998006775-A1 | AQUEOUS BONDING COMPOSITION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-02-19 | — | — | WO | claimed |
| EP-0305968-A2 | Compositions against protozoal diseases | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1989-03-08 | — | — | EP | claimed |